The DOI matches its Crossref record.
Body mass index and clinical response to infliximab in rheumatoid arthritis
Abstract
Objective: Adipose tissue has immunomodulating effects in rheumatoid arthritis (RA), although the exact role is, at present, unclear. The purpose of this study was to determine whether body mass index (BMI) affects response to infliximab in RA patients investigated prospectively. Methods: In 89 patients with active RA, the BMI was calculated before initiation of infliximab treatment (3 mg/kg intravenously). After 16 weeks of treatment, changes in disease activity were assessed with the Disease Activity Score in 28 joints (DAS28). Results: The mean ± SD BMI was 26 ± 5 kg/m 2 (range 17–42). The BMI correlated positively with the DAS28 at baseline (r = 0.34, P = 0.001). Since selection of study patients according to DAS28 values could influence the clinical response to tumor necrosis factor (TNF) blockade due to regression to the mean because the clinical response is itself based on the change in the DAS28 values, analysis of covariance was used to correct for the baseline DAS28. A highly significant, negative association between the BMI and the absolute decrease in the DAS28 after 16 weeks (P = 0.001) was found also when adjusted for anti–citrullinated protein antibodies. Conclusion: Although the infliximab dosage is based on body weight, RA patients with a high BMI responded less well to infliximab, a finding that held true when adjusted for the baseline DAS28 or anti–citrullinated protein antibody status. These results support the notion that adipose tissue may be involved in the pathophysiology of RA and could have implications for other immune‐mediated inflammatory conditions treated with TNF antagonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Obesity in autoimmune diseases: Not a passive bystander
Versini, M., Jeandel, P.-Y., Rosenthal, E., & Shoenfeld, Y. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.07.001 · Cited by 694
Ordás, I., Mould, D. R., Feagan, B. G., & Sandborn, W. J. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.328 · Cited by 498
Turner, D., Ruemmele, F. M., Orlanski‐Meyer, E., Griffiths, A. M., de Carpi, J. M., Bronsky, J., Veres, G., Aloi, M., Strisciuglio, C., Braegger, C. P., et al. (2018) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000002035 · Cited by 481
Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes
Singh, S., Dulai, P. S., Zarrinpar, A., Ramamoorthy, S., & Sandborn, W. J. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.181 · Cited by 452
Eichler, H.-G., Abadie, E., Breckenridge, A., Flamion, B., Gustafsson, L. L., Leufkens, H., Rowland, M., Schneider, C. K., & Bloechl-Daum, B. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3501 · Cited by 369
Metadata
- Authors
- Klaasen, R., Wijbrandts, C. A., Gerlag, D. M., & Tak, P. P.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2011-01-28
- Volume
- 63
- Issue
- 2
- Pages
- 359-364
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2163498804
- Cited by
- 188
- References
- 0
- FWCI
- 6.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Body mass index and clinical response to infliximab in rheumatoid arthritis. https://app.cochat.ai/papers/10.1002/art.30136
- The paper
- Klaasen, R., Wijbrandts, C. A., Gerlag, D. M., & Tak, P. P. (2011). Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis & Rheumatism. https://doi.org/10.1002/art.30136
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.